Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure
Background Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term QOL changes in sRV failure patients treated wi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/12/1/e003009.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575618755067904 |
|---|---|
| author | Philippine Kiès Marieke Nederend Ralph M.L. Neijenhuis Anna E. van Groningen Monique R.M. Jongbloed Hubert W. Vliegen J. Wouter Jukema Anastasia D. Egorova |
| author_facet | Philippine Kiès Marieke Nederend Ralph M.L. Neijenhuis Anna E. van Groningen Monique R.M. Jongbloed Hubert W. Vliegen J. Wouter Jukema Anastasia D. Egorova |
| author_sort | Philippine Kiès |
| collection | DOAJ |
| description | Background Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term QOL changes in sRV failure patients treated with sacubitril/valsartan.Methods In this single-centre, prospective cohort study, patients with symptomatic sRV failure completed the Netherlands Organisation for Applied Scientific Research/Academic Hospital Leiden Questionnaire for Adult’s Health-Related Quality of Life (TAAQOL) at baseline and after starting treatment with sacubitril/valsartan. The TAAQOL was taken at structured outpatient follow-up moments after 6, 12, 24 and 36 months of treatment. Linear mixed effects models were used to evaluate the medium-term changes in 12 QOL domains.Results Of 40 sRV failure patients initiated on sacubitril/valsartan, 35 completed the titration phase, and 31 filled in a total of 98 TAAQOL questionnaires (response rate 77.5%). Significant improvements in gross motoric functioning (p=0.008), cognitive function (p=0.002), sleep (p=0.041), social functioning (p<0.001) and daily activities (p=0.001) were observed during follow-up. No significant changes were observed in fine motoric functioning, pain, sexuality, vitality, positive, depressive or aggressive emotions. Of interest, periods with restrictions relating to the COVID-19 pandemic did not significantly influence changes over time in any of the 12 QOL domains.Conclusions Sacubitril/valsartan treatment was associated with persistent medium-term QOL improvements in gross motoric functioning, cognitive function, sleep, social functioning and daily activities domains in sRV failure patients. Self-perceived QOL of sRV failure patients may be amenable to improvement with sacubitril/valsartan. |
| format | Article |
| id | doaj-art-d5dd110de51d449cbcee2fb834a49342 |
| institution | Kabale University |
| issn | 2053-3624 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Open Heart |
| spelling | doaj-art-d5dd110de51d449cbcee2fb834a493422025-01-31T22:25:08ZengBMJ Publishing GroupOpen Heart2053-36242025-01-0112110.1136/openhrt-2024-003009Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failurePhilippine Kiès0Marieke Nederend1Ralph M.L. Neijenhuis2Anna E. van Groningen3Monique R.M. Jongbloed4Hubert W. Vliegen5J. Wouter Jukema6Anastasia D. Egorova7Department of Cardiology, Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsCenter for Congenital Heart Disease Amsterdam Leiden (CAHAL), Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsCenter for Congenital Heart Disease Amsterdam Leiden (CAHAL), Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsCenter for Congenital Heart Disease Amsterdam Leiden (CAHAL), Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsDepartment of Cardiology, Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsCenter for Congenital Heart Disease Amsterdam Leiden (CAHAL), Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsDepartment of Cardiology, Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsCenter for Congenital Heart Disease Amsterdam Leiden (CAHAL), Leiden University Medical Center, Leiden, Zuid-Holland, NetherlandsBackground Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. This study aimed to evaluate the medium-term QOL changes in sRV failure patients treated with sacubitril/valsartan.Methods In this single-centre, prospective cohort study, patients with symptomatic sRV failure completed the Netherlands Organisation for Applied Scientific Research/Academic Hospital Leiden Questionnaire for Adult’s Health-Related Quality of Life (TAAQOL) at baseline and after starting treatment with sacubitril/valsartan. The TAAQOL was taken at structured outpatient follow-up moments after 6, 12, 24 and 36 months of treatment. Linear mixed effects models were used to evaluate the medium-term changes in 12 QOL domains.Results Of 40 sRV failure patients initiated on sacubitril/valsartan, 35 completed the titration phase, and 31 filled in a total of 98 TAAQOL questionnaires (response rate 77.5%). Significant improvements in gross motoric functioning (p=0.008), cognitive function (p=0.002), sleep (p=0.041), social functioning (p<0.001) and daily activities (p=0.001) were observed during follow-up. No significant changes were observed in fine motoric functioning, pain, sexuality, vitality, positive, depressive or aggressive emotions. Of interest, periods with restrictions relating to the COVID-19 pandemic did not significantly influence changes over time in any of the 12 QOL domains.Conclusions Sacubitril/valsartan treatment was associated with persistent medium-term QOL improvements in gross motoric functioning, cognitive function, sleep, social functioning and daily activities domains in sRV failure patients. Self-perceived QOL of sRV failure patients may be amenable to improvement with sacubitril/valsartan.https://openheart.bmj.com/content/12/1/e003009.full |
| spellingShingle | Philippine Kiès Marieke Nederend Ralph M.L. Neijenhuis Anna E. van Groningen Monique R.M. Jongbloed Hubert W. Vliegen J. Wouter Jukema Anastasia D. Egorova Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure Open Heart |
| title | Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure |
| title_full | Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure |
| title_fullStr | Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure |
| title_full_unstemmed | Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure |
| title_short | Sacubitril/valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure |
| title_sort | sacubitril valsartan is associated with improvements in quality of life in adult congenital heart disease patients with systemic right ventricular failure |
| url | https://openheart.bmj.com/content/12/1/e003009.full |
| work_keys_str_mv | AT philippinekies sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT mariekenederend sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT ralphmlneijenhuis sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT annaevangroningen sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT moniquermjongbloed sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT hubertwvliegen sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT jwouterjukema sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure AT anastasiadegorova sacubitrilvalsartanisassociatedwithimprovementsinqualityoflifeinadultcongenitalheartdiseasepatientswithsystemicrightventricularfailure |